Literature DB >> 6023770

Nature of the renal concentrating defect in sickle cell disease.

F E Hatch, J W Culbertson, L W Diggs.   

Abstract

Free water reabsorption (T(c) (H2O)) measured during 10% mannitol diuresis and subsequently during 3% saline diuresis was compared in patients with sickle cell anemia and in normal subjects. During mannitol infusion, T(c) (H2O) progressively rose with increasing osmolar clearance (C(osm)) and reached a maximal level in both groups studied. During hypertonic saline diuresis, T(c) (H2O) progressively rose in the normal subjects and exceeded the maximal levels attained during mannitol diuresis, with no evidence of a maximal T(c) (H2O) level appearing. In contrast, none of the saline curves significantly exceeded the mannitol curves in the sickle cell patients but tended to parallel the mannitol curves at comparable rates of solute clearance. Since T(c) (H2O) is an index of both solute (sodium) transport from the loop of Henle and solute accumulation in the hypertonic medullary interstitium, tubular sodium handling was examined in both sickle cell patients and control subjects alike. No difference in the tubular transport of sodium could be demonstrated either under conditions of sodium loading or under conditions in which the tubular sodium load was low (water diuresis). These data support the conclusion that the defect in urinary concentration in sickle cell patients is caused by a limitation in maintaining a high concentration of solute in the medullary interstitium, thus limiting the rate of T(c) (H2O) from the collecting duct.

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 6023770      PMCID: PMC297054          DOI: 10.1172/JCI105535

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  MICROPUNCTURE STUDY OF HYPERTONIC SODIUM CHLORIDE LOADING IN THE RAT.

Authors:  G GIEBISCH; R M KLOSE; E E WINDHAGER
Journal:  Am J Physiol       Date:  1964-04

2.  Sickling phenomenon produced by hypertonic solutions: a possible explanation for the hyposthenuria of sicklemia.

Authors:  P E PERILLIE; F H EPSTEIN
Journal:  J Clin Invest       Date:  1963-04       Impact factor: 14.808

3.  A histologic appraisal of the kidney in sickle cell anemia.

Authors:  J BERNSTEIN; C F WHITTEN
Journal:  Arch Pathol       Date:  1960-10

4.  The renal concentrating defect in sickle cell disease.

Authors:  M F LEVITT; A D HAUSER; M S LEVY; D POLIMEROS
Journal:  Am J Med       Date:  1960-10       Impact factor: 4.965

5.  Hematuria in sickie cell disease.

Authors:  W M LUCAS; W H BULLOCK
Journal:  J Urol       Date:  1960-05       Impact factor: 7.450

6.  Production of hypertonic urine in the absence of pituitary antidiuretic hormone.

Authors:  R W BERLINER; D G DAVIDSON
Journal:  J Clin Invest       Date:  1957-10       Impact factor: 14.808

7.  Renal failure and other unusual manifestations in sickle-cell trait.

Authors:  M TELLEM; A I RUBENSTONE; A M FRUMIN
Journal:  AMA Arch Pathol       Date:  1957-05

8.  The renal clearance of alkali-stable inulin.

Authors:  M WALSER; D G DAVIDSON; J ORLOFF
Journal:  J Clin Invest       Date:  1955-10       Impact factor: 14.808

9.  Renal hemodynamic studies in adults with sickle cell anemia.

Authors:  J N ETTELDORF; J D SMITH; A H TUTTLE; L W DIGGS
Journal:  Am J Med       Date:  1955-02       Impact factor: 4.965

10.  The mechanism of formation of osmotically concentrated urine during the antidiuretic state.

Authors:  G A ZAK; C BRUN; H W SMITH
Journal:  J Clin Invest       Date:  1954-07       Impact factor: 14.808

View more
  10 in total

1.  Management of sickle cell disorders.

Authors:  A J Bellingham
Journal:  Proc R Soc Med       Date:  1974-10

2.  Hyposthenuria in sickle cell disease.

Authors:  Y F Francis; H G Worthen
Journal:  J Natl Med Assoc       Date:  1968-07       Impact factor: 1.798

3.  Identification of ceruloplasmin as a biomarker of chronic kidney disease in urine of sickle cell disease patients by proteomic analysis.

Authors:  Marina Jerebtsova; Santosh L Saraf; Xionghao Lin; Gillian Lee; Elena Afia Adjei; Namita Kumari; Nowah Afangbedji; Rasha Raslan; Charlee McLean; Victor R Gordeuk; Sergei Nekhai
Journal:  Am J Hematol       Date:  2017-11-27       Impact factor: 10.047

4.  Urinary orosomucoid is associated with progressive chronic kidney disease stage in patients with sickle cell anemia.

Authors:  Marina Jerebtsova; Santosh L Saraf; Simran Soni; Nowah Afangbedji; Xionghao Lin; Rasha Raslan; Victor R Gordeuk; Sergei Nekhai
Journal:  Am J Hematol       Date:  2018-02-05       Impact factor: 10.047

5.  Elimination of the fibrinogen integrin αMβ2-binding motif improves renal pathology in mice with sickle cell anemia.

Authors:  Md Nasimuzzaman; Paritha I Arumugam; Eric S Mullins; Jeanne M James; Katherine VandenHeuvel; Marilou G Narciso; Maureen A Shaw; Sarah McGraw; Bruce J Aronow; Punam Malik
Journal:  Blood Adv       Date:  2019-05-14

6.  Effects of Senegal haplotype (Xmn1-rs7412844), alpha-thalassemia (3.7kb HBA1/HBA2 deletion), NPRL3-rs11248850 and BCL11A-rs4671393 variants on sickle cell nephropathy.

Authors:  El Hadji Malick Ndour; Khuthala Mnika; Fatou Guèye Tall; Moussa Seck; Indou Dème Ly; Victoria Nembaware; Hélène Ange Thérèse Sagna-Bassène; Rokhaya Dione; Aliou Abdoulaye Ndongo; Jean Pascal Demba Diop; Nènè Oumou Kesso Barry; Moustapha Djité; Rokhaya Ndiaye Diallo; Papa Madièye Guèye; Saliou Diop; Ibrahima Diagne; Aynina Cissé; Ambroise Wonkam; Philomène Lopez Sall
Journal:  Int J Biochem Mol Biol       Date:  2022-04-15

7.  Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia.

Authors:  Santosh L Saraf; Xu Zhang; Tamir Kanias; James P Lash; Robert E Molokie; Bharvi Oza; Catherine Lai; Julie H Rowe; Michel Gowhari; Johara Hassan; Joseph Desimone; Roberto F Machado; Mark T Gladwin; Jane A Little; Victor R Gordeuk
Journal:  Br J Haematol       Date:  2013-12-12       Impact factor: 6.998

8.  Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG).

Authors:  Scott T Miller; Winfred C Wang; Rathi Iyer; Sohail Rana; Peter Lane; Russell E Ware; Daner Li; Renée C Rees
Journal:  Pediatr Blood Cancer       Date:  2010-02       Impact factor: 3.167

Review 9.  Dysnatremias in patients with kidney disease.

Authors:  Sara Combs; Tomas Berl
Journal:  Am J Kidney Dis       Date:  2013-11-14       Impact factor: 8.860

Review 10.  Endothelin receptor antagonists in sickle cell disease: A promising new therapeutic approach.

Authors:  Brandon M Fox; Malgorzata Kasztan
Journal:  Life Sci       Date:  2016-04-03       Impact factor: 5.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.